Year None2022202120202019201820172016 Date Latest Press Release November 14, 2016 Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting November 14, 2016 Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program November 8, 2016 Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results October 24, 2016 Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection October 19, 2016 Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection October 17, 2016 Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA) October 13, 2016 Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting September 7, 2016 Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School September 6, 2016 Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th September 1, 2016 Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016 Pagination First page « first Previous page ‹ previous … Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Page 22 Next page next › Last page last »
